JOURNAL ASMAC No 5 - octobre 2018

PERSPECTIVES
32. Nicholls SJ, Puri R, Anderson T, et al.: Effect
of evolocumab on progression of coronary
disease in statin-treated patients: The
GLAGOV randomized clinical trial. JAMA
2016; 316: 2373–2384.
33. Sabatine MS, Giugliano RP, Keech AC, et al.:
Evolocumab and clinical outcomes in patients
with cardiovascular disease. N Engl J
Med 2017; 376: 1713–1722.
34. Blom DJ, Hala T, Bolognese M, et al.: A 52-
week placebo-controlled trial of evolocumab
in hyperlipidemia. N Engl J Med 2014; 370:
1809–1819.
35. Sabatine MS, Giugliano RP, Wiviott SD, et al.:
Efficacy and safety of evolocumab in reducing
lipids and cardiovascular events. N Engl
J Med 2015; 372: 1500–1509.
36. Roth EM, McKenney JM: ODYSSEY MONO: effect
of alirocumab 75 mg subcutaneously every
2 weeks as monotherapy versus ezetimibe over
24 weeks. Future Cardiol 2015; 11: 27–37.
37. Koren MJ, Lundqvist P, Bolognese M, et al.:
Anti-PCSK9 monotherapy for hypercholesterolemia:
the MENDEL-2 randomized, controlled
phase III clinical trial of evolocumab.
J Am Coll Cardiol 2014; 63: 2531–2540.
38. Heigl F, Hettich R, Lotz N, et al.: Efficacy,
safety, and tolerability of long-term lipoprotein
apheresis in patients with LDL- or Lp(a)
hyperlipoproteinemia: Findings gathered
from more than 36000 treatments at one
center in Germany. Atheroscler Suppl 2015;
18: 154–162.
39. Schettler VJ, Neumann CL, Peter C, et al.: The
German Lipoprotein Apheresis Registry
(GLAR) - almost 5 years on. Clin Res Cardiol
Suppl 2017; 12 (Suppl 1): 44–49.
40. Cuchel M, Meagher EA, du Toit Theron H, et
al.: Phase 3 HoFH Lomitapide Study investigators.
Efficacy and safety of a microsomal
triglyceride transfer protein inhibitor in patients
with homozygous familial hypercholesterolaemia:
a single-arm, open-label,
phase 3 study. Lancet 2013; 381: 40–46.
41. Corsini A, Ceska R: Drug-drug interactions
with statins: will pitavastatin overcome the
statins› Achilles› heel? Curr Med Res Opin
2011; 27: 1551–1562.
42. Swiss Atherosclerosis Association. www.agla.
ch. Letzter Zugriff: 6.7.2017.
43. Mach F, Noll G, Riesen WF, Sudano I: PCSK9-
Hemmung mit Antikörpern: die Resultate
der Phase-III Studienprogramme. Cardiovasc
Med 2017; 20: 123–131.
Antworten zu den Lernfragen
1. Alle Antworten sind richtig.
2. Antworten a) und c) sind richtig.
3. Antworten a), b), c) und e) sind richtig.
Photo: Pierre-Yves Massot. Espace publicitaire offert.
Du rire et du rêve pour nos enfants hospitalisés
Grâce à vos dons, les enfants hospitalisés reçoivent
chaque semaine la visite des docteurs Rêves.
Merci pour votre soutien.
CCP 10-61645-5 | theodora.org
VSAOJournal_178x133_CH-F-D.indd 1 11.04.17 16:15
N° 5 Octobre 2018
VSAO JOURNAL ASMAC
49